Netherlands-headquartered drugmaker Mylan (Nasdaq: MYL) was nearly 5% down in pre-market trading on Friday, having closed 4% lower on Thursday.
Uncertainty over the impact of the coronavirus was likely the main cause, though investors might have noted a couple of other uncertain factors in looking to the year ahead as Mylan presented its financial results for the latest quarter and 2019 as a whole.
These factors include the merger with Pfizer’s (NYSE: PFE) Upjohn unit for off-patent branded drugs, which is still to close, and a looming lawsuit over alleged anti-competitive practices relating Mylan’s EpiPen (epinephrine) devices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze